BI's faldaprevir under FDA review in HCV; firm halts deleobuvir development
This article was originally published in Scrip
Executive Summary
The FDA has accepted for review the new drug application (NDA) for Boehringer Ingelheim's faldaprevir, an oral protease inhibitor, as part of a combination antiviral regimen to treat chronic HCV infection in adults who are treatment-naive or have been previously treated with interferon-based treatment, as well as those with compensated liver disease, cirrhosis or HCV/HIV co-infection, the company revealed on 6 March.